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CURRENT THERAPEUTICS
Management Of Atrial Fibrillation
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Summary
Atrial fibrillation is the most commonly encountered sustained arrhythmia. The spectrum of symptomatology and
presentation are broad. The goals of treatment should include (1) identification of any underlying cause(s) and/or
precipitating factor(s), (2) control of ventricular rate, (3) restoration and maintenance of sinus rhythm and (4)
prevention of thromboembolism. The characteristics of the arrhythmia differ among patients; hence, some goals will
apply in some cases and a different combination in other cases. A thoughtful, individualized approach is essential.
(HKPract 1997;19:601-613)
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Background
Atrial f i b r i l l a t i on (AF) is
certainly the most common of all the
arrhythmia requ i r ing t rea tment
interventions. In the United States,
the prevalence of both chronic' and
paroxysmal AF increases dramatically
with age, from 0.2% to 0.3% in
individuals less than 40 years of age,
to 5% to 9% in those between 60-90
years old. 1 In Hong Kong, an
incidence of 1.3% was documented in
a recent survey.2 AF affects men and
women approximately equally. In an
ageing population, AF will become an
increasing burden to the health care
system. The development of AF
carries an ominous prognosis, since it
is followed by a near ly doubled
overall mortality rate and a greater
t h a n t w o - f o l d c a r d i o v a s c u l a r
mortality compared with subjects who
did not have AF.3 The clinical
man i f e s t a t i on of AF are h ighly
variable, ranging from complete
absence of symptoms to haemody-
namic col lapse. The rapid and
irregular rhythm and the loss of
synchronized atrial activity both
con t r i bu t e to decreased cardiac
performance and symptomatology
(Table 1).
Classification of AF
(A) New o n s e t AF - f i r s t
presentation of AF in which a
proper classification is pending.
(B) Paroxysmal AF - AF that termi-
nates spontaneously, usually
within 48 hours.
(C) Persistent AF - sinus rhythm is
restored either by medical or
electrical means.
* Address for correspondence: Prof. Chu-Pak Lau, Chief, Division of Cardiology, Department of Medicine, University of Hong Kong, Queen Mary
Hospital, Hong Kong.
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(D) Permanent AF - AF in which
restoration of sinus rhythm either
fails or is considered clinically
inappropriate because of low
success rate.
It is noteworthy that all cases of
AF belonging to (B)-(D) are chronic
in the sense that they are e i ther
r ecu r ren t or l o n g - s t a n d i n g .
Depending on the vigor of the patient
and/or physician in restoring sinus
rhythm, some cases of permanent AF
may be classified as persistent under
different scenario.
Basic principles of manage-
ment
The management of AF should
address five key cl inical concerns:
1. Identify any underlying cause(s)
and/or precipitating factor(s).
2. Control rapid ventricular rate, if
present, with atrioventricular
(AV) blocking drugs.
3. Decide whether restoration of
sinus rhythm is a possible or
desirable goal.
4. Decide how best to main ta in
s i n u s r h y t h m , shou ld s i n u s
rhythm be restored.
5. Initiate long-term anticoagula-
tion or antiplatelet therapy for
prevention of thromboembolism.
Table 1: Presentation of atrial fibrillation
Asymptomatic
Rate-related symptoms
« palpitation
• ischaemia
• haemodynamic
Symptoms related to loss of atrial contraction / AV synchrony
• palpitation
• haemodynamic
• malaise, fatigue, reduced exercise tolerance
Complications
• emboli
• syncope
• tachycardia-related cardiomyopathy
Table 2: Causes and/or precipitating factors for atrial fibrillation
Structural Heart Diseases
• Hypertensive heart disease
• Coronary artery disease: Acute infarction, chronic
ventricular dysfunction
• Valvular heart disease, especially mitral valve disease
• Cardiomyopathies: Dilated, hypertrophic, and restrictive
• Post-operative, especially open heart surgery
• Pericarditis
• Congential heart disease
Identification of the under-
lying cause(s)
In every patient presenting with
AF, it is important to consider the
possible underlying cause(s) and/or
precipitating factor(s) (Table 2).
Systemic Conditions
• Systemic infection(s)
• Thyroid disease: Hyperthyroidism, hypothyroidism
• Electrolyte imbalance, especially hypokalaemia
• Malignancy, especially lung and mediastinal
• Alcoholism
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Treatment of the underlying cause or on the basis of a 12-lead electrocar- diseases may p reven t AF, e.g.
reversal of a precipitating factor may diogram (ECG) (Figure 1). However, r a d i o f r e q u e n c y ab la t ion of the
control the ventricular rate or restore
sinus rhythm. A careful history and
physical examina t ion should be
performed to f i nd out these
potentially reversible cause(s). The
diagnosis of AF can be made easily
any additional ECG features e.g. left
ventricular hypertrophy or presence of
Wolf f -Park inson-Whi te (WPW)
syndrome, that are suggestive of the
underlying causes should be noted.
Curative therapy for the underlying
accessory pathway in patients with
WPW syndrome (Figure 2). All
patients presenting with new onset
AF should have their thyroid status
measured and transthoracic echocar-
diography performed. Echocardio-
Figure 1: Electrocardiographic appearances of atrial fibrillation
10mm/mV125mm/s
aVR
III aVF
(a) Fine atria! fibrillation
I - I - E 10Mi/mU;:5n«>/s
aVR
aVL TTYTY
V,
r
aVF
(b) Coarse atrial fibrillation
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graphy provides a va luab le
assessment of the left ventricular
function and to detect the presence of
any structural heart disease, such as
hypertensive heart disease or mitral
stenosis. Echocardiography is usually
underused in both general and
hospital practice.4
Control of ventricular rate
In patients wi th normal AV
conduction, the ventricular response
during AF is typically between 70-
120 beats per minute (bpm) at rest,
and h i g h e r d u r i n g s y m p a t h e t i c
activation e.g. exercise. Patients with
AF often present with signs and
symptoms of circulatory insufficiency
owing to an inappropriately rapid
ventricular rate. Considerable
symptomatic relief can be obtained by
adminis ter ing drugs that slow AV
conduction and ven t r i cu la r rate.
Furthermore, control of ventricular
rate may prevent the development of
left ventricular dysfunction due to
tachycardiomyopathy.5-6 It is
important to consider in every patient
with AF
(1) whether ventricular rate control
is necessary;
(2) how quickly control needs to be
achieved; and
(3) which drug is to be used.
Those patients who are haemo-
dynamically unstable or who have
acute pulmonary edema due to a rapid
AF requires urgent synchronized DC
cardioversion. However, most stable
AF pa t ien t s wi th pers i s ten t
t achyca rd ia (> 100 bpm) at rest
should be treated with AV nodal
blocking agents (see below) to slow
ventricular rate. However, in patients
with aberrant and wide QRS complex
Figure 2: Electrocardiographic appearance of Wolff-
Parkinson-White syndrome during
(a) Sinus rhythm
(b) Atrial fibrillation
(c) After successful radiofrequency ablation
(Continued on page 607)
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that are suggestive of the presence of
a c c e s s o r y p a t h w a y w i t h p re -
excitation, AV nodal blocking agents
are contraindicated (Figure 3).
Acute rate control
D i g o x i n , be t a -b locke r s and
calcium channel blockers with AV
nodal blocking properties (verapamil
or diltiazem) singly or in combination
a r e e f f e c t i v e i n r e d u c i n g t h e
ventricular rate in AF patients. The
agent and route of adminis t ra t ion
used are determined by the clinical
charac ter i s t ics and presen ta t ion
(Table 3). In t ravenous therapy is
i n d i c a t e d fo r c o n t r o l o f r ap id
Figure 3: Left atrial appendage (LAA) thrombi revealed by tran-
soesphageal echocardiography in a patient with atrial
fibrillation (LA = left atrium)
Table 3: Therapies for acute control of the ventricular rate in atrial fibrillation
Clinical Setting Drug
Rapid rate,
hypotensive
Rapid rate,
symptomatic
Dose
None
Diltiazem
Verapamil
Metoprolol
IV bolus 20 mg or 0.25 mg/kg over
2 min followed if necessary by IV
25 mg or 0.35 mg/kg 15 min later.
Maintenance infusion of 5-15 mg/h.
IV 5-10 mg over 2-3 min. Repeat 5-
10 mg 30 min later if required.
Maintenance infusion rate is not well
documented.
IV 5 mg every 5 rain, total 15 mg.
Propranolol IV 1-5 mg (1 mg every 2 min)
Efficacy
Rapid rate
control
Good rate
control
Rapid rate
control
Rapid rate
control
Esmolol
Digoxin
Slow rate, stable None
IV 0.5 mg/kg over 1 min. Repeat if Short-acting
necessary. Maintenance infusion
0.05 mg/kg/min.
IV 0.25 - 0.5 mg (total 1 mg/24 hr) Moderate to
low efficacy
Comments
Urgent DC cardioversion
Well t o l e r a t e d . May be
synergistic with digoxin with no
effect on digoxin levels.
Hypotension may occur. May be
synergistic with digoxin but also
increases digoxin levels.
Useful in post-operative setting,
c a u t i o n i n p a t i e n t s w i t h
congestive heart failure.
Useful in post-operative setting,
c a u t i o n i n p a t i e n t s w i t h
congestive heart failure.
Useful in post-operative setting,
hypotension is common.
Delayed onset of AV node
slowing (hours)
No therapy
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symptomatic vent r icular rates.
Intravenous digoxin does not provide
immediate heart rate control, onset
occurs anywhere from 1 to 6 hours,
while maximum efficacy may not be
seen for up to 24 hours. However, it
is particularly desirable in patients
whose AF is a complication of, or is
associated with congestive heart
failure. Intravenous beta-blocker, may
be used to control the ventricular rate
especially in situation with high
sympathetic drive e.g. post-operative.
Both intravenous diltiazem and
int ravenous verapamil are very
effective with rapid onset of action. In
general, both drugs are well tolerated
but should be avoided in patients with
hypotension and severe left
ventricular dysfunction.
Long term rate control
In the majority of AF patients,
long term oral therapy is appropriate
(Table 4). Digoxin therapy remains
the mainstay of monotherapy for
sustained AF in most sedentary
patients or in those requiring
inotropic support. Calcium channel
blockers with AV nodal properties
(verapamil or diltiazem) may have
some advantage over beta-blocker for
control of ventricular rate in AF
because they have vasodilator
properties that partially offset their
negative inotropic effects. Beta-
blockers and calc ium c h a n n e l
blockers and AV nodal blocking
properties (verapamil or diltiazem)
either used alone or in combination
with digoxin, may provide better
overall control of ventricular rate in
chronic AF especia l ly d u r i n g
exercise.7-8 For those patients with
persistent rapid AF despite adequate
drug therapy with AV nodal blocking
agents, they may benef i t from
radiofrequency ablation of AV node
and implantation of a ventricular or
dual-chamber rate adaptive pace-
maker.9
Table 4: Therapies for chronic control of the ventricular rate in atrial fibrillation
Rapid
120 .
Atenolol 25 - 100 mg daily
: 10 ~ 120 mg
Digoxin 0.1-0.75 mg daily
Comments .• . . . ; ; : ::
Reduce rest and exercise
may cause ankle
and exercise rate.
Especially effective to Any beta-blocker may be used
reduce exercise rate'.-:':; ••:•; ' ' • . - . . . . " • ; : ;. .... v';'.' ^
Especially effective to;' • . : . : ' - ' • • ' ' - : : ; : . : . ; - . . ; . ' • •• /
Delayed onset of AV node
slowing (hours). Minimally
effective during exercise, fever,
and other high cate-cholamine
status. Caution in elderly
patients or those with renal
Reduces testing rate
Rapid symptom-
atic ventricular
rate despi te
. medical therapy,
AV junction ablation and
permanent pacemaker
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Restoration of sinus rhythm
The two mos t c o m p e l l i n g
reasons to consider eliminating AF
and restoring sinus rhythm are:
(1) r e s t i t u t i o n of organized and
e f f e c t i v e a t r i a l m e c h a n i c a l
function and
(2) prevention of thromboembolism.
Only 30-50% of pa t ien ts wi th
recent onset of AF wi l l revert
spontaneously to s inus rhythm
w i t h i n 48 hours . E l e c t i v e
c a r d i o v e r s i o n i s p r o b a b l y
indicated for all patients with a
f i r s t episode of AF unless
relative contraindications exist
s u c h t h a t t he b e n e f i t s o f
restoring and/or the chance of
ma in ta in ing s inus rhythm are
m i n i m a l (Table 5) . E i t h e r
synchronized electrical shock or
p h a r m a c o l o g i c t h e r a p y can
achieve cardioversion of AF.
Unless AF occurred within 48
hours , medical or electr ical
c a r d i o v e r s i o n s h o u l d b e
p r e c e d e d by a p e r i o d of
anticoagulation for 3-4 weeks.10
Alternative strategy is to perform
a transoesphageal echocardio-
graphy to exclude left atrial
thrombi (Figure 3) together with
i n t r a v e n o u s hepar in before
ca rd iovers ion . " It is also
imperative to continue anticoag-
ulation for 3-4 weeks after return
of sinus rhythm, as most of the
thromboembolic events occur
after restoration of sinus rhythm
when effective atrial contraction
resumes. The general efficacy of
external defibrillation is about
70%. Recent ly , low energy
biphasic shocks delivered via
catheters between the right and
Table 5: Relative contraindication for elective cardioversion
Poor prognosis (i.e. advanced malignancy)
High risk from anaesthesia (i.e. severe respiratory disease)
Other severe functional limitations
Long standing AF (years)
Left atrial dimension > 6 cm
Minimal or no symptom with a well-controlled ventricular rate
le f t a t r ia are associated w i t h
signif icant ly higher successful
rate of cardioversion compared
w i t h e x t e r n a l d e f i b r i l l a t i o n
w i t h o u t a n y i nc r ea se i n
complication.12
Pharmacological cardioversion
Class IA, Class IC, and Class III
antiarrhythmic drugs are all modestly
effective in restoring and maintaining
s inus rhy thm (Table 6). For all
agents, the successful rate (30-80%)
of cardioversion is related to the
durat ion of AF and conversion of
long standing AF is unl ikely . All
these agents have a r i sk of
proarrhythmia especially in patients
wi th s t ruc tu ra l heart disease.13, 1 4
Thus, these agents should preferably
be administrated in the hospital under
careful moni tor ing. If the chosen
p h a r m a c o l o g i c a l agent has not
achieved conversion in 24 hours,
direct DC synchronized shock is
usually required for cardioversion.
Concomitant antiarrhythmic agent
increases the chance that s inus
rhy thm wil l be mainta ined after
ca rd iovers ion . All pa t ien ts on
an t i a r rhy t hm i c agent should be
monitored for proarrhythmia for up to
24 hours fol lowing restoration of
sinus rhythm.15
Electrical cardioversion
DC synchronized shock may be
the first l ine therapy or may be used
in combinat ion wi th an t ia r rhythmic
drug therapy with a successful rate up
to 90%. The procedure is performed
af ter f a s t i n g and unde r general
anaesthesia or deep sedation. Cardiac
mon i to r ing and f u l l resusci ta t ion
equipment should be available. DC
synchronized shocks are delivered via
defibrillation patches placed in apex-
anterior or anterior-posterior position.
Ini t ia l ly , 100 J wil l be used, and if
unsuccessful, followed with up to 3
addi t iona l shocks of 360 J each,
usually with different patch positions.
Maintenance of sinus
rhythm
P a t i e n t s wi th r e v e r s i b l e
under ly ing cause or precipitating
f a c t o r s h o u l d b e c o r r e c t e d .
Infrequent episodes of AF can be
managed with repeated pharmaco-
logical or electrical cardioversion.
However, when occurrences are more
frequent and very likely, considera-
t ion must be given to long term
maintenance with ant iarrhythmic
agents (Table 6). While there seems
to be little agreement regarding the
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Table 6:. Antiarrhythmic drug therapy in atrial fibrillation
Drag
Class IA
Quinidine
gluconate
Dose
PO 1.2 - 1.6g/day
in divided dose
Procainamide PO 1 g, then up to
500 mg 3 hourly, IV
100 mg bolus over 2
min up to 25 mg/
min to 1 g, then 2 -
6 mg/min.
Disopyramide PO 100-200 mg 6
hourly. Loading
dose 300 mg
Class IC
Flecainide
Propafenone
PO 75-150mg BD.
IV l-2mg/kg over
10 min, then 0.15 -
0.25 mg/kg/h.
PO 150 - 300 mg
TDS. IV 2mg/kg
then 2 mg/min,
Class III
Sotalol
Amiodarone
PO 80-240mg BD
PO loading 1200 -
1 600 mg d a i l y ,
maintenance 200 -
400mgQD
Useful in
Renal failure
Men, short term
therapy
Women
Vagally mediated
AF
Patients wi thou t
h e a r t d i s e a s e .
Failure of Class IA
drags
Patients w i t h o u t
h e a r t d i s e a s e .
Failure of Class IA
drugs
IHD
Failure of Class IA
or IC drug
CHF. Failure of
other drug. Renal
failure
Avoid in
Liver failure
Heart failure
Renal failure
Heart failure
Joint disease
Renal failure
Heart failure
Glaucoma
Heart failure, IHD
Heart failure
Comments
Vagolytic. Many side effects
including diarrhea, nausea, torsades
de pointes and hypotension.
Monitor QRS, QT, plasma K
Torsades de pointes rare.
Hypotension with IV dose. Limit
oral use to 6 months to reduce the
risk of drug-induced lupus
Vagolytic (urinary retention, dry
mouth) and negative inotropic
effects.
Hypotension and torsades de
pointes.
Proarrhythmia. Negative inotropic.
CNS effects. Increased incidence
of sudden death postinfarct.
Proarrhythmia. Modest negative
inotropic effect. Gastrointestinal
side-effect.
Heart failure Sinus bradycardia, AV block,
Where beta-blocker is negative inotropic, torsades if
contraindicated hypokalemic
Young patients
Pulmonary disease
Thyroid dysfunction
Many side effects including
pulmonary fibrosis, gastrointestinal
upset, thyroid dysfunction, eye and
skin changes.
Torsades uncommon.
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efficacy of several antiarrhythmic
agents to prevent recurrence of AF,
great concerns have been raised
relative to the long term safety of
these agents and their possible
negative impact on patient's survival.
Patients with a history of congestive
heart failure and underlying structural
heart disease seem to be at greatest
r isk of adverse effects from
antiarrhythmic agents (especially
Class IA and IC agents).13'14 If long
term antiarrhythmic therapy is
selected to maintain sinus rhythm,
patients should be seen regularly and
monitored for proarrhythmia. Class
IA and III drugs prolong the QT
interval and may give rise to a
polymorphic ventricular tachycardia
called Torsades de Pointes. ECG
should be monitored during initiation
of these drugs, and it is wise to avoid
a greater than 25% to 30% increase in
the QT interval or a corrected QT
interval exceeding 500 msec.
Although the proarrhythmic risk is
lower wi th amiodarone , o ther
potentially serious side effects that
involve the thyroid, lungs, skin, and
nervous system may occur, especially
wi th long-term and higher-dose
therapy. At follow-up patients should
be questioned about possible side
effects (Table 6).
Non-pharmacological methods
have recent ly been explored to
main ta in s inus r h y t h m due to
limitation of pharmacological therapy
as described above. Surgical method
with "Maze procedure" that involves
breaking the potential re-entry circuits
in the atria by making a series of
incision in each atrium is associated
with 95% cure rate for AF. However,
it is a major operation that requires
open-heart surgery and carries a 1 %
to 5% morbidity and mortality.16
Recently, catheter-based procedures
with radiofrequency energy applica-
tion to focal source of AF or to atrial
tissue to mimic surgical maze have
been a t t empted wi th va r i ab le
success.17-18 Furthermore, a new form
of pacing, biatrial pacing has been
suggested to prevent AF in patients
with drug refractory paroxysmal AF.19
Finally, early data has suggested that
implantable atrial defibrillators is a
feasible, safe and effective method for
cardioversion of AF, but its long term
clinical efficacy is still unclear.18
Although the preliminary results of
these new therapies for AF seem
promising, further clinical studies are
required to prove their usefulness
before any recommendations can be
made.
Table 7; Summary of the randomized trial of anticoagulation in atrial fibrillation
Embolic Event
..... %/Year :
Trial
BAATF24
CAFA25
SPINAF26
AFASAK27
SPAF28
SPAF II29
Sample Size INR
420
378
525
1007
1330
1100
1.5-2.7
2.0 - 3.0
1.4-2.8
2:8 - 4.2
2.0-4.5
2.0 - 4.5
Control
,;3.0:; ::;
4.6
~::4.3: •
','.&
7,4
.9 (aspirin)
Warfarin
".':: 0.4
3.4
y 0.9 :
2.9
2.3
1.3
%Risk
Reduction
86
45 :'""
79
58
67
67
Comment
Aspirin 75 mg, no benefit
Aspirin 375 mg, associated
with a 42% risk reduction
AFASAK = The Copenhagen AFASAK Study
BAATF = Boston Area Anticoagulation Trial for Atrial Fibrillation
CAFA = Canadian Atrial Fibrillation Anticoagulation
INR = international normalized ratio
SP1NAF = Stroke Prevention in Nonrheumatic Atrial Fibrillation
SPAF = Stroke Prevention in Atrial Fibrillation
SPAF II = Stroke Prevention in Atrial Fibrillation II
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Preventing thromboembo-
lism with chronic antico-
agulation and antiplatelet
therapy
The most serious complication
of AF is thromboembolism which is
frequently cerebral (> 90%) and may
result in a large stroke (>50%). In
fact, recent studies have shown that
stroke related to AF is usually more
severe and is associated with two-fold
increase in mortali ty as compared
w i t h s t r o k e d u e t o o t h e r
aetiologies.2 1 '2 2 Most i s c h a e m i c
strokes associated w i t h AF are
probably due to embolism of stasis-
induced thrombi forming in the left
atrium and particularly its appendage.
However , p e r h a p s 25% of AF
associated wi th stroke is due to
associated intrinsic cerebrovascular
disease, other cardiac sources of
embolism, or aortic arch atheroma.23
The high risk of thromboembo-
lism in AF associated with valvular
heart disease is wel l known.
However, AF even in the absence of
v a l v u l a r disorders s t i l l carries a
substantial risk of thromboembolism.
The rate of stroke among elder ly
people with AF averages 3% to 7%
per year, about six t imes that of
p e o p l e w i t h o u t AF.2 3 T h u s ,
prevention of thromboembolism is
one of the most i m p o r t a n t
considerations regarding long-term
management of patients with AF.
Ant icoagula t ion wi th warfar in is
highly effective for reducing stroke in
AF patients. Five large, multi-centre
r a n d o m i z e d t r i a l 2 4 - 2 9 u s i n g
international normalized ratio (INR)
ranges of approximately 1.8 to 4.2
showed a mean reduction in stroke of
Table 8: Risk
High Risk Variables
1. Structural heart disease risk factors
• Left ventricular systolic dysfunction
• Left atrial enlargement
• Congestive heart failure
• Valvular heart disease
• Coronary artery disease
2. Systemic risk factors
• Age > 65 years
• Prior thromboembolic event
• Hypertension
• Diabetes
nearly 70% in patients assigned to
receiving anticoagulation (Table 7).
The inc rementa l r i sk of serious
bleeding was less than 1% per year.
The r i sk reduct ion s ign i f i can t ly
outweighed the slightly increased risk
of serious bleeding, especially in
patients with coexistent risk factors
for stroke. In a more generalized
outpatient population, risk of bleeding
may be greater and low- in tens i ty
an t icoagu la t ion (INR 2.0 to 3.0)
clearly confers benefit.
The absolute rate of stroke varies
important ly with patient age and
coexistent cardiovascular disease.
Stratification of AF patients into
those at high and low risk throm-
boembolism is a crucial determinant
of opt imal an t icoagula t ion pro-
phylaxis (Table 8). The decision to
anticoagulate a patient with AF must
be individualized, and assessment of
bleeding risk from anticoagulation
must always be considered. For high
risk group, an t i coagu la t ion with
warfarin is recommended to achieve
an INR of 2.0 to 3.0. In patient with
lower r isk of thromboembolism,
ant icoagula t ion is not requi red .
Higher dose aspirin (325 mg daily)
also reduces the risk of stroke, its
effects are more modest (approxi-
mately 20% reduction) and should be
considered in patients in whom
anticoagulation is contraindicated or
in low risk population. •
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